CEBPA and acute myeloid leukemia: In AML patients, deregulation of CEBPA function is a common event comprising of genomic mutations (Pabst et al, 2001a; Frohling et al, 2004; Nerlov, 2004), transcriptional and post-transcriptional suppression (Pabst et al, 2001b; Helbling et al, 2004; Helbling et al, 2005), and inactivation by phosphorylation (Radomska et al, 2006).